Meeting
2014 ASCO Annual Meeting
Transcriptional expression of Bcl-2 as predictive of response to neoadjuvant chemotherapy with trastuzumab in HER2-positive ER-positive breast cancer patients.
Authors
Maki Tanioka
Medical Oncology, Hyogo Cancer Center, Akashi, Japan
Maki Tanioka , Kazuko Sakai , Tamotsu Sudo , Toshiko Sakuma , Kouichi Hirokaga , Shintaro Takao , Hironobu Minami , Shunichi Negoro , Kazuhiko Nakagawa , Kazuto Nishio
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 602)
DOI
10.1200/jco.2014.32.15_suppl.602
Abstract #
602
Poster Bd #
66
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Assessment of ESR1 and ERBB2 mutations in estrogen receptor positive (ER+) metastatic breast cancers (MBC).
First Author: Gargi D. Basu
Poster
2011 ASCO Annual Meeting
Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis.
First Author: G. Bianchini
Poster
2023 ASCO Annual Meeting
The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.
First Author: Tarek Mohamed Ahmed Abdel-Fatah
First Author: Neal A. Fischbach